CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16 enrolled
Drug / intervention
Remifentanildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01901575
NCT01901575Phase 4Completed
CompareCT.gov

Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia

NYU Langone Health·interventional·Posted Jul 17, 2013·Updated Jan 2, 2018

In Brief

A Phase 4 clinical trial evaluating Remifentanil for Tachycardia, Ventricular. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Determine effects of remifentanil conscious sedation in patients undergoing Electrophysiological (EP) studies for the ablation of idiopathic ventricular tachycardia and/or persistent frequent premature ventricular contractions (PVCs) of non-ischemic origin

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTachycardia, Ventricular
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 17, 2013
Enrollment StartJul 1, 2011
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.0 years ago

Interventions

Remifentanildrug

Patients with established PVC's , sedated with remifentanil IVPCA per study protocol